Synthesis and SAR studies of imidazo-[1,2-a]-pyrazine Aurora kinase inhibitors with improved off-target kinase selectivity
作者:Matthew E. Voss、Matthew P. Rainka、Mike Fleming、Lisa H. Peterson、David B. Belanger、M. Arshad Siddiqui、Alan Hruza、Johannes Voigt、Kimberly Gray、Andrea D. Basso
DOI:10.1016/j.bmcl.2012.03.051
日期:2012.5
The structure–activity relationships of new Aurora A/B kinase inhibitors derivedfrom the previously identified kinase inhibitor 12 are described. Introduction of aceticacidamides onto the pyrazole of compound 12 was postulated to influence Aurora A/B selectivity and improve the profile against off-target kinases. The SAR of the aceticacidamides was explored and the effect of substitution on enzyme
描述了源自先前鉴定的激酶抑制剂12的新型Aurora A / B激酶抑制剂的构效关系。假定将乙酰胺引入化合物12的吡唑中会影响Aurora A / B的选择性并改善针对脱靶激酶的作用。探索了乙酸酰胺的SAR,并研究了取代对酶抑制的影响以及基于机理的细胞活性。另外,筛选了几种更有效的抑制剂的脱靶激酶选择性。
WO2008/156614
申请人:——
公开号:——
公开(公告)日:——
Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors
作者:David B. Belanger、Michael J. Williams、Patrick J. Curran、Amit K. Mandal、Zhaoyang Meng、Matthew P. Rainka、Tao Yu、Neng-Yang Shih、M. Arshad Siddiqui、Ming Liu、Seema Tevar、Suining Lee、Lianzhu Liang、Kimberly Gray、Bohdan Yaremko、Jennifer Jones、Elizabeth B. Smith、Dan B. Prelusky、Andrea D. Basso
DOI:10.1016/j.bmcl.2010.08.140
日期:2010.11
We report a series of potent imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors. Optimization of the solvent accessible 8-position led to improvements in both oral bioavailability and off-target kinase inhibition. Compound 25 demonstrates anti-tumor activity in an A2780 ovarian tumor xenograft model. (C) 2010 Elsevier Ltd. All rights reserved.
Discovery of a Potent, Injectable Inhibitor of Aurora Kinases Based on the Imidazo-[1,2-<i>a</i>]-Pyrazine Core
作者:Tao Yu、Jayaram R. Tagat、Angela D. Kerekes、Ronald J. Doll、Yonglian Zhang、Yushi Xiao、Sara Esposite、David B. Belanger、Patrick J. Curran、Amit K. Mandal、M. Arshad Siddiqui、Neng-Yang Shih、Andrea D. Basso、Ming Liu、Kimberly Gray、Seema Tevar、Jennifer Jones、Suining Lee、Lianzhu Liang、Samad Ponery、Elizabeth B. Smith、Alan Hruza、Johannes Voigt、Lata Ramanathan、Winifred Prosise、Mengwei Hu
DOI:10.1021/ml100063w
日期:2010.8.12
The imidazo-[1,2-a]-pyrazine (1) is a dual inhibitor of Aurora kinases A and B with modest cell potency (IC50 = 250 nM) and low solubility (5 mu M). Lead optimization guided by the binding mode led to the acyclic amino alcohol 12k (SCH 1473759), which is a picomolar inhibitor of Aurora kinases (TdF K-d Aur A = 0.02 nM and Aur B = 0.03 nM) with improved cell potency (phos-HH3 inhibition IC50 = 25 nM) and intrinsic aqueous solubility (11.4 mM). It also demonstrated efficacy and target engagement in human tumor xenograft mouse models.
New geldanamycin derivatives with anti Hsp properties by mutasynthesis
hygroscopicus, the geldanamycin producer, with 21 aromatic and heteroaromatic amino acids provided new nonquinoid geldanamycin derivatives. Large scale (5 L) fermentation provided four newderivatives in sufficient quantity for full structural characterisation. Among these, the first thiophene derivative of reblastatin showed strong antiproliferative activity towards several human cancer cell lines.